15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Adaptive Biotechnologies Corp, 5 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $19.00 to $28.00, a moderate spread. The average target of $24.42 is roughly in line with the current $24.35. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 4% this year and 22% next, consensus EPS building from about $-0.06 next quarter toward $-0.18 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy583%
Hold117%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Adaptive Biotechnologies Corp.
As of Sep, 5 of 6 firms rate ADPT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ADPT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.08 – $-0.04 · 7 analysts · -30% YoY
Next period, 7 analysts expect Adaptive Biotechnologies Corp to earn $-0.06 a share (range $-0.08 – $-0.04), versus $-0.09 a year earlier. Full-year consensus is $-0.54, growing to $-0.18 the year after.
REVENUE · NEXT QUARTER
$79.0M
Range $77.3M – $83.0M · 7 analysts · -25% YoY
Revenue is expected to reach $79.0M (range $77.3M – $83.0M), -25.0% year-over-year. Full-year consensus is $293.2M, rising to $358.5M next year.
Top analysts covering Adaptive Biotechnologies Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ADPT.
#1
SJ
Sung Ji Nam
Scotiabank · Rank #140
Buy
$12.00-50.7% to target
Overall win rate
46%
+ Follow
#2
David Westenberg
Piper Sandler · Rank #244
Buy
$27.50+12.9% to target
Overall win rate
33%
+ Follow
#3
Mark Massaro
BTIG
Buy
$25.00+2.7% to target
Coverage
—
+ Follow
#4
SS
Sebastian Sandler
JP Morgan
Buy
$27.00+10.9% to target
Coverage
—
+ Follow
#5
Subbu Nambi
Guggenheim
Buy
$25.00+2.7% to target
Coverage
—
+ Follow
ADPT stock forecast FAQ
What is ADPT's average 12-month price target?+
The 6 analysts with a live target average $24.42 for Adaptive Biotechnologies Corp over the next 12 months, ranging from a $28.00 high to a $19.00 low.
Is ADPT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 5 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ADPT?+
The Street-high target is $28.00 (TD Cowen), and the Street-low is $19.00 (JP Morgan). The average of all 6 active targets is $24.42.
How many Wall Street analysts cover ADPT?+
6 analysts have an active rating on Adaptive Biotechnologies Corp, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering ADPT?+
Among analysts who currently cover ADPT, Sung Ji Nam of Scotiabank has the strongest overall Quantellect track record (Rank #140). Their current call is Buy with a $12.00 target.
What is Adaptive Biotechnologies Corp's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.08 – $-0.04) across 7 analysts. Full-year EPS is projected at $-0.54, rising to $-0.18 the following year.
How much revenue is Adaptive Biotechnologies Corp expected to report next quarter?+
Consensus revenue is $79.0M (range $77.3M – $83.0M). Full-year revenue is projected at $293.2M, growing to $358.5M next year.
Have analysts been upgrading or downgrading ADPT lately?+
As of Sep, 5 of 6 firms rate ADPT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ADPT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
